BNB Plus Corp(BNBX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 4 at 4:00 PM ET (Korea 11/5 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -39.93 | Insider Own | 30.48% | Shs Outstand | 5.7M | Perf Week | - |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.0M | Perf Month | -62.09% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 11.98% | Short Float | 3.47% | Perf Quarter | -68.65% |
| Income | -0.05B | P/S | 0.56 | EPS this Y | - | Inst Trans | -3.95% | Short Ratio | 0.17 | Perf Half Y | -88.91% |
| Sales | 0.00B | P/B | 0.07 | EPS next 5Y | - | ROA | -256.09% | Short Interest | 0.17M | Perf YTD | -86.75% |
| Book/sh | 2.21 | P/C | 1.23 | EPS past 3/5Y | 78.76% 69.38% | ROE | -297.4% | 52W High | -97.72% ($7.15) | Perf Year | -96.83% |
| Cash/sh | 0.13 | P/FCF | - | Sales past 3/5Y | -51% 2.04% | ROIC | -275.69% | 52W Low | 7.17% ($0.15) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 92.56% | Gross Margin | 33.6% | Volatility(W/M) | 11.12% 10.98% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -0.08 | Sales Y/Y TTM | -44.78% | Oper. Margin | -1080.61% | ATR (14) | 0.06 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.74 | EPS Q/Q | 99.7% | Profit Margin | -2388.97% | RSI (14) | 21.9 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.82 | Sales Q/Q | 4.14% | SMA20 | -57.72% ($0.38) | Beta | 0.6 | Target Price | $1125 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -62.72% ($0.43) | Rel Volume | 0 | Prev Close | $0.16 |
| Employees | 26 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -89.83% ($1.57) | Avg Volume(3M) | 1.04M | Price | $0.16 |
| IPO | 2001/10/18 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
(BNB Plus) was originally a nucleic acid production and DNA tagging company operating under the name Applied DNA Sciences, but in October 2025 it changed its corporate name to BNB Plus Corp. and switched its ticker to BNBX, adding the BNB digital asset treasury strategy as a core business. It is listed on the US Nasdaq. The company also continues to operate its existing DNA and RNA production business through its LineaRx subsidiary, along with its DNA tagging business for industrial supply chains.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
BNBX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $56. Peers typically go for $304.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +64% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #138 of 138 in the industry
Based on market cap of $1M.
EQS#134 Equus Total Return Inc $9M PER - 
ALP#135 Alpha Compute Corp $5M PER - 
TWAV#135 TaoWeave Inc $5M PER - 
CWD#137 CaliberCos Inc $5M PER - BNBX#138 BNB Plus Corp $1M PER - 
FAQ
What kind of company is BNBX?
BNBX belongs to the Financial sector and operates in the Asset Management industry.
What is the market cap of BNBX?
The market cap of BNBX is approximately $1M, ranking 5,880 within its sector.
What is the 52-week high and low for BNBX?
BNBX has recorded a 52-week high of $7.15 and a low of $0.15.
